Trial Profile

Reverse Triple Negative Immune Resistant Breast Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Choline (Primary) ; Efavirenz (Primary) ; Sodium cromoglicate (Primary)
Indications Advanced breast cancer; Triple negative breast cancer
Focus Pharmacodynamics; Therapeutic Use
Acronyms Renaissance

Most Recent Events

29 Sep 2022 According to ClinicalTrials.gov record, protocol has been amended to increase patient number from 20 to 30, treatment arm changed from 2 to 3
29 Sep 2022 Planned number of patients changed from 20 to 30.
01 Apr 2022 Planned initiation date changed from 15 Oct 2021 to 1 Apr 2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com